Bristol Myers Squibb EPS - Earnings per Share 2010-2023 | BMY
Bristol Myers Squibb annual and quarterly earnings per share history from 2010 to 2023. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Bristol Myers Squibb EPS for the quarter ending March 31, 2023 was $1.07, a 81.36% increase year-over-year.
- Bristol Myers Squibb EPS for the twelve months ending March 31, 2023 was $3.43, a 21.63% increase year-over-year.
- Bristol Myers Squibb 2022 annual EPS was $2.95, a 5.45% decline from 2021.
- Bristol Myers Squibb 2021 annual EPS was $3.12, a 178.2% decline from 2020.
- Bristol Myers Squibb 2020 annual EPS was $-3.99, a 298.51% decline from 2019.
| Bristol Myers Squibb Annual EPS |
| 2022 |
$2.95 |
| 2021 |
$3.12 |
| 2020 |
$-3.99 |
| 2019 |
$2.01 |
| 2018 |
$3.01 |
| 2017 |
$0.61 |
| 2016 |
$2.65 |
| 2015 |
$0.93 |
| 2014 |
$1.20 |
| 2013 |
$1.54 |
| 2012 |
$1.16 |
| 2011 |
$2.16 |
| 2010 |
$1.79 |
| 2009 |
$5.34 |
| Bristol Myers Squibb Quarterly EPS |
| 2023-03-31 |
$1.07 |
| 2022-12-31 |
$0.95 |
| 2022-09-30 |
$0.75 |
| 2022-06-30 |
$0.66 |
| 2022-03-31 |
$0.59 |
| 2021-12-31 |
$1.07 |
| 2021-09-30 |
$0.69 |
| 2021-06-30 |
$0.47 |
| 2021-03-31 |
$0.89 |
| 2020-12-31 |
$-4.43 |
| 2020-09-30 |
$0.82 |
| 2020-06-30 |
$-0.04 |
| 2020-03-31 |
$-0.34 |
| 2019-12-31 |
$-0.73 |
| 2019-09-30 |
$0.83 |
| 2019-06-30 |
$0.87 |
| 2019-03-31 |
$1.04 |
| 2018-12-31 |
$0.71 |
| 2018-09-30 |
$1.16 |
| 2018-06-30 |
$0.23 |
| 2018-03-31 |
$0.91 |
| 2017-12-31 |
$-1.40 |
| 2017-09-30 |
$0.51 |
| 2017-06-30 |
$0.56 |
| 2017-03-31 |
$0.94 |
| 2016-12-31 |
$0.53 |
| 2016-09-30 |
$0.72 |
| 2016-06-30 |
$0.69 |
| 2016-03-31 |
$0.71 |
| 2015-12-31 |
$-0.12 |
| 2015-09-30 |
$0.42 |
| 2015-06-30 |
$-0.08 |
| 2015-03-31 |
$0.71 |
| 2014-12-31 |
$0.01 |
| 2014-09-30 |
$0.43 |
| 2014-06-30 |
$0.20 |
| 2014-03-31 |
$0.56 |
| 2013-12-31 |
$0.43 |
| 2013-09-30 |
$0.42 |
| 2013-06-30 |
$0.32 |
| 2013-03-31 |
$0.37 |
| 2012-12-31 |
$0.57 |
| 2012-09-30 |
$-0.43 |
| 2012-06-30 |
$0.38 |
| 2012-03-31 |
$0.64 |
| 2011-12-31 |
$0.51 |
| 2011-09-30 |
$0.56 |
| 2011-06-30 |
$0.52 |
| 2011-03-31 |
$0.57 |
| 2010-12-31 |
$0.28 |
| 2010-09-30 |
$0.55 |
| 2010-06-30 |
$0.53 |
| 2010-03-31 |
$0.43 |
| 2009-12-31 |
$4.05 |
| 2009-09-30 |
$0.48 |
| 2009-06-30 |
$0.49 |
| 2009-03-31 |
$0.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$137.942B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
